The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in previously treated adults with BRAF V600E-mutated metastatic colorectal cancer (CRC).
“As the first-and-only targeted regimen for people with BRAF-mutant metastatic CRC who have received prior therapy, [encorafenib] in combination with cetuximab is a much-needed new treatment option,” noted investigator Scott Kopetz, MD, PhD, an associate professor of gastrointestinal